A Study of Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

Open to people ages 18 years and up

• Participants with Myelodysplastic Syndrome (MDS) defined according to World Health Organization classification, with Revised International Prognostic Scoring System (IPSS-R) prognostic risk category of intermediate, high, or very high risk.
• Adequate performance status and hematological, liver, and kidney function.

• Immediate eligibility for allogenic stem cell transplant (SCT), as determined by the investigator, with an available donor.
• Prior treatment with Cluster of Differentiation (CD) 47 or Signal-regulatory protein alpha (SIRPα)-targeting agents.
• Any prior antileukemic therapy for treatment of intermediate, high, very high risk MDS per IPSS-R.
• Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which participants are not on active anticancer therapies and have had no evidence of active malignancy for at least ≥ 1 year.
• Contraindications to azacitidine.
• Clinical suspicion of active central nervous system (CNS) involvement by MDS.
• Known active or chronic hepatitis B or C infection or human immunodeficiency virus in medical history .
• Active hepatitis B virus and/or active hepatitis C virus, and/or HIV following testing at screening.
• Pregnancy or active breastfeeding.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.